NCT00282295 - US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease | Biotech Hunter

Enrollment

1,344

Participants

Timeline

Start Date

January 25, 2006

Primary Completion Date

August 8, 2006

Study Completion Date

August 8, 2006

Conditions

Acellular PertussisTetanusDiphtheria

Interventions

BIOLOGICAL

Boostrix®

GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

BIOLOGICAL

Menactra™

Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.

Trial Locations (24)

14534

GSK Investigational Site, Pittsford

14620

GSK Investigational Site, Rochester

15227

GSK Investigational Site, Pittsburgh

15241

GSK Investigational Site, Pittsburgh

16125

GSK Investigational Site, Greenville

16505

GSK Investigational Site, Erie

16508

GSK Investigational Site, Erie

19140

GSK Investigational Site, Philadelphia

21401

GSK Investigational Site, Annapolis

21702

GSK Investigational Site, Frederick

30062

GSK Investigational Site, Marietta

40202

GSK Investigational Site, Louisville

44118

GSK Investigational Site, University Heights

68178

GSK Investigational Site, Omaha

72205

GSK Investigational Site, Little Rock

76508

GSK Investigational Site, Temple

80401

GSK Investigational Site, Golden

84084

GSK Investigational Site, West Jordan

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

85224

GSK Investigational Site, Chandler

92708

GSK Investigational Site, Fountain Valley

08889

GSK Investigational Site, Whitehouse Station

44308-1062

GSK Investigational Site, Akron